MST melanoma and ccRCC targets were just assumptions from their historical reports a few years back.
They valued at ~$5 from memory so they have actually devalued as a result of CPACS, KPACS and DACS.
they are assuming a DCF for a licensing deal even though a buyout is perhaps more likely. my guess is a DXB style licensing rollout.
I could be wrong but I think there is nothing to see here as it’s just based on the old programs not all comers CPACS. It’s just to peak new investor interests whilst we wait on trials and news.
Ann: Race In-person Investor Briefing Invitation Perth, page-18
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.82 |
Change
-0.005(0.27%) |
Mkt cap ! $309.9M | |||
| Open | High | Low | Value | Volume |
| $1.83 | $1.86 | $1.79 | $157.7K | 86.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5623 | $1.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.82 | 9999 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |